Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma

scientific article

Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.LEUKRES.2003.11.002
P698PubMed publication ID15120936

P50authorHagop KantarjianQ60394812
Francis J GilesQ62066745
Maher AlbitarQ66429840
Susan M O'BrienQ87633434
Julie M VoseQ87934467
James O ArmitageQ87934469
Taghi ManshouriQ91467065
Philip J BiermanQ116794963
R Gregory BociekQ117253702
Marcella M JohnsonQ117253759
P2093author name stringKim-Anh Do
P433issue6
P304page(s)595-604
P577publication date2004-06-01
P1433published inLeukemia ResearchQ15716445
P1476titleClinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma
P478volume28

Reverse relations

cites work (P2860)
Q46979566A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma.
Q53222523Angiogenesis-related growth factors and cytokines in the serum of patients with B non-Hodgkin lymphoma; relation to clinical features and response to treatment.
Q33999348Angiogenin: a review of the pathophysiology and potential clinical applications
Q53221535Clinical correlations and prognostic relevance of HGF, VEGF AND FGF expression in Brazilian patients with non-Hodgkin lymphoma.
Q42261011Clinical significance of serum hepatocyte growth factor (HGF) levels in hepatocellular carcinoma
Q47920503Current status and future prospects of biomarkers in the diagnosis of hepatocellular carcinoma.
Q30490554Diagnosis of hepatocellular carcinoma.
Q64915467Discriminant analysis involving serum cytokine levels and prediction of the response to therapy of patients with Hodgkin lymphoma.
Q46193990Does serum soluble vascular endothelial growth factor levels have different importance in pediatric acute leukemia and malignant lymphoma patients?
Q61795626Hepatocyte Growth Factor: A Microenvironmental Resource for Leukemic Cell Growth
Q36646078High MET gene copy number predicted poor prognosis in primary intestinal diffuse large B-cell lymphoma
Q53173084Inhibition of c-MET is a potential therapeutic strategy for treatment of diffuse large B-cell lymphoma.
Q28080705Lymphoma: immune evasion strategies
Q38751343Microenvironmental interactions between endothelial and lymphoma cells: a role for the canonical WNT pathway in Hodgkin lymphoma.
Q28079232Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies
Q33406444Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma
Q38968332Role of vascular endothelial growth factor C in classical Hodgkin lymphoma.
Q53485702Serum VEGF as a significant marker of treatment response in hodgkin lymphoma.
Q60340626Serum angiogenin levels predict treatment response in patients with stage IV melanoma
Q45280594Serum vascular endothelial growth factor-a levels during induction therapy in children with acute lymphoblastic leukemia
Q51733952The prognostic significance of VEGF-C and VEGF-A in non-Hodgkin lymphomas.
Q41953798VEGF and bFGF gene polymorphisms in patients with non-Hodgkin's lymphoma.

Search more.